Precision Medicine (also known as personalized medicine) refers to a medical approach that tailors prevention, diagnosis, and therapy to the individual characteristics of a patient—specifically their genetic, molecular, phenotypic, and environmental characteristics. In contrast to traditional medicine, which is oriented toward population averages, precision medicine aims to identify the right treatment for the right patient at the right time. In clinical research, this approach has led to fundamental changes in study design, biomarker development, diagnostic co-development, and regulatory assessment, and is permanently transforming the way clinical evidence is generated and evaluated.
Biomarkers and Companion Diagnostics
At the heart of precision medicine is the identification and validation of predictive biomarkers—biological features that predict which patients will respond to a specific therapy. Key categories include:
- Genomic biomarkers: Gene mutations, copy number variations, fusion genes, or gene expression signatures that predict response to a targeted therapy (e.g., EGFR mutation in non-small cell lung cancer).
- Protein-based biomarkers: Overexpression of receptors or signaling molecules that serve as therapeutic targets (e.g., HER2 overexpression in breast cancer).
- Companion Diagnostics (CDx): In vitro diagnostics that are regulatory-approved alongside a medicinal product and whose use is required for the safe and effective application of the drug. The EMA and FDA frequently require a co-developed CDx for targeted therapies.
- Liquid Biopsy: Non-invasive analysis of circulating tumor DNA (ctDNA) or circulating tumor cells from blood samples, enabling real-time monitoring of therapy response and the development of resistance. Liquid biopsy assays are increasingly being developed as companion diagnostics and are already regulatory-approved for several oncological indications.
Study Designs in Precision Medicine
Precision medicine requires innovative study designs that go beyond the classic two-arm RCT:
- Basket Trials: Investigate a therapy in patients with the same molecular feature (biomarker), regardless of tumor location or histology. These allow for simultaneous testing across multiple indications.
- Umbrella Trials: Investigate multiple targeted therapies in patients with the same disease, who are stratified into different arms based on biomarkers.
- Adaptive Enrichment Designs: Begin with a broad population and focus during the course of the study on subgroups with the best response (biomarker-positive patients).
- N-of-1 Trials: Individualized crossover studies at the single-patient level that directly compare which therapy works best for a specific patient. Although N-of-1 trials are methodologically challenging, they are gaining importance in rare disease research and personalized oncology.
Regulatory Requirements
The regulatory assessment of precision medicine products is complex, as drugs and diagnostics are often developed and evaluated together. The EMA has published dedicated guidelines for targeted therapies and biomarker stratification. The EMA’s Adaptive Pathways program enables a staggered approval approach for targeted therapies in clearly defined biomarker-selected populations. In the US, the FDA is driving the Precision Medicine Initiative and has established a Breakthrough Therapy Designation pathway for precision medicine approaches with particular therapeutic potential. Furthermore, the FDA has established an Accelerated Approval pathway for biomarker-driven therapies with previously unmet medical needs.
Relevance for clinical trials
Precision medicine is fundamentally changing clinical research: instead of large, unselected study populations, smaller, biomarker-selected cohorts are investigated, which increases statistical power and can shorten development times. At the same time, new challenges arise in patient recruitment, biobanking, and the development of regulatory-accepted diagnostics. Full-service CROs like mediconomics support sponsors in biomarker-driven study planning, the co-development of companion diagnostics, regulatory strategy for basket and umbrella trials, and the preparation of biomarker data for EMA and FDA marketing authorization applications. Likewise, mediconomics assists in the preparation of scientific advice requests regarding biomarker-supported therapy strategies. This support also includes the development of statistical analysis plans for biomarker-stratified populations and regulatory communication regarding biomarker validation requirements.
Frequently Asked Questions (FAQ)
What is the difference between predictive and prognostic biomarkers?
A prognostic biomarker predicts the course of the disease regardless of therapy (e.g., high tumor grading as an unfavorable prognostic factor). A predictive biomarker predicts the differential response to a specific therapy—i.e., whether a patient will benefit from a specific treatment or not. In precision medicine, predictive biomarkers are central as they enable patient selection for targeted therapies.
What is a Companion Diagnostic and when is it required?
A Companion Diagnostic (CDx) is a regulatory-approved in vitro diagnostic device that is essential for the safe and effective use of a corresponding medicinal product. The EMA and FDA may link the approval of a targeted drug to the simultaneous availability of a validated CDx. CDx are developed in parallel with the drug and must guide biomarker selection in clinical trials.
How do Basket Trials differ from Umbrella Trials?
In a basket trial, a therapy is investigated in patients with the same biomarker across different tumor entities. In an umbrella trial, multiple therapies are investigated in patients with the same tumor entity, who are stratified into different treatment arms based on various biomarkers. Both designs enable efficient, biomarker-driven efficacy testing in small populations.
Regulatory References
- EMA Guideline on the Use of Minimal Residual Disease as a Clinical Endpoint in Multiple Myeloma (2021) – Example of precision medicine endpoints
- EMA Adaptive Pathways Pilot Programme: Final Report (2016) and guidance on staggered approvals
- FDA Guidance: Enrichment Strategies for Clinical Trials (2019): Biomarker selection and adaptive enrichment
- ICH E15 – Definitions for Genomic Biomarkers, Pharmacogenomics and Related Terminology (2007)
- EU Regulation (EU) 2017/746 (IVDR): Requirements for companion diagnostics as in vitro diagnostic medical devices